Emerging therapies for Duchenne muscular dystrophy

T Markati, M Oskoui, MA Farrar, T Duong… - The Lancet …, 2022 - thelancet.com
Duchenne muscular dystrophy is an X-linked disease caused by the absence of functional
dystrophin in the muscle cells. Major advances have led to the development of gene …

CRISPR therapeutics for Duchenne muscular dystrophy

E Erkut, T Yokota - International journal of molecular sciences, 2022 - mdpi.com
Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder with
a prevalence of approximately 1 in 3500–5000 males. DMD manifests as childhood-onset …

Innovative therapeutic approaches for Duchenne muscular dystrophy

F Fortunato, R Rossi, MS Falzarano… - Journal of Clinical …, 2021 - mdpi.com
Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy
affecting~ 1: 5000 live male births. Following the identification of pathogenic variations in the …

Effects of exosome-mediated delivery of myostatin propeptide on functional recovery of mdx mice

N Ran, X Gao, X Dong, J Li, C Lin, M Geng, HF Yin - Biomaterials, 2020 - Elsevier
Duchenne muscular dystrophy (DMD) is a devastating disorder caused by loss of functional
dystrophin protein, resulting in muscle wasting. Enhancing muscle growth by inhibiting …

The DMD gene and therapeutic approaches to restore dystrophin

F Fortunato, M Farnè, A Ferlini - Neuromuscular Disorders, 2021 - Elsevier
Duchenne muscular dystrophy (DMD) is a severe X-linked disease characterized by
progressive muscle weakness. It is caused by a variety of DMD gene pathogenic variations …

Restoring dystrophin expression in Duchenne muscular dystrophy: current status of therapeutic approaches

Y Shimizu-Motohashi, H Komaki, N Motohashi… - Journal of personalized …, 2019 - mdpi.com
Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive
muscle weakness, is caused by the absence or a decreased amount of the muscle …

Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse

N Wein, TA Vetter, A Vulin, TR Simmons… - … Therapy-Methods & …, 2022 - cell.com
Duchenne muscular dystrophy (DMD) is typically caused by mutations that disrupt the DMD
reading frame, but nonsense mutations in the 5′ part of the gene induce utilization of an …

Safety and efficacy of DT-DEC01 therapy in Duchenne muscular dystrophy patients: A 12-month follow-up study after systemic intraosseous administration

M Siemionow, G Biegański, A Niezgoda… - Stem Cell Reviews and …, 2023 - Springer
Abstract Duchenne Muscular Dystrophy (DMD) is a progressive and fatal muscle-wasting
disease with no known cure. We previously reported the preliminary safety and efficacy up to …

Long-term protective effect of human dystrophin expressing chimeric (DEC) cell therapy on amelioration of function of cardiac, respiratory and skeletal muscles in …

M Siemionow, P Langa, S Brodowska… - Stem Cell Reviews and …, 2022 - Springer
Abstract Duchenne Muscular Dystrophy (DMD) is a lethal disease caused by mutations in
dystrophin encoding gene, causing progressive degeneration of cardiac, respiratory, and …

Dystrophin expressing chimeric (DEC) cell therapy for duchenne muscular dystrophy: a first-in-human study with minimum 6 months follow-up

A Heydemann, G Bieganski, J Wachowiak… - Stem Cell Reviews and …, 2023 - Springer
Abstract Duchenne Muscular Dystrophy (DMD) is a X-linked progressive lethal muscle
wasting disease for which there is no cure. We present first-in-human study assessing safety …